Tildrakizumab Post-Authorisation Safety Study (PASS) in European Psoriasis Registries (M-14745-40)

First published 01/12/2020

Last updated 10/03/2025

EU PAS number:

EUPAS37946

Study

Ongoing

Download as PDF

Documents

Study protocol

No information provided.

Study results

No information provided.

Study report

No information provided.

ENCePP Seal

The use of the ENCePP Seal has been discontinued since February 2025. The ENCePP Seal fields are retained in the display mode for transparency but are no longer maintained.

No information provided.

Tildrakizumab Post-Authorisation Safety Study (PASS) in European Psoriasis Registries (M-14745-40)

Secondary tabs

Share this page